21. Sacituzumab govitecan, an antibody‐drug conjugate targeting trophoblast cell‐surface antigen 2, shows cytotoxic activity against poorly differentiated endometrial adenocarcinomas in vitro and in vivo. Issue 3 (14th January 2020) Authors: Perrone, Emanuele; Manara, Paola; Lopez, Salvatore; Bellone, Stefania; Bonazzoli, Elena; Manzano, Aranzazu; Zammataro, Luca; Bianchi, Anna; Zeybek, Burak; Buza, Natalia; Tymon‐Rosario, Joan; Altwerger, Gary; Han, Chanhee; Menderes, Gulden; Huang, Gloria S.; Ratner, Elena; Silasi, Dan‐Arin; Azodi,... Journal: Molecular oncology Issue: Volume 14:Issue 3(2020) Page Start: 645 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
22. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Issue 3 (23rd September 2014) Authors: English, Diana P.; Bellone, Stefania; Schwab, Carlton L.; Roque, Dana M.; Lopez, Salvatore; Bortolomai, Ileana; Cocco, Emiliano; Bonazzoli, Elena; Chatterjee, Sudeshna; Ratner, Elena; Silasi, Dan‐Arin; Azodi, Masoud; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D. Journal: Cancer Issue: Volume 121:Issue 3(2015) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
23. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy‐resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo. Issue 3 (23rd September 2014) Authors: English, Diana P.; Bellone, Stefania; Schwab, Carlton L.; Roque, Dana M.; Lopez, Salvatore; Bortolomai, Ileana; Cocco, Emiliano; Bonazzoli, Elena; Chatterjee, Sudeshna; Ratner, Elena; Silasi, Dan‐Arin; Azodi, Masoud; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D. Journal: Cancer Issue: Volume 121:Issue 3(2015) Page Start: 403 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
24. The Role of the Immune System in Ovarian Cancer and Implications on Therapy. (2nd June 2016) Authors: Menderes, Gulden; Schwab, Carlton L.; Black, Jonathan; Santin, Alessandro D. Journal: Expert review of clinical immunology Issue: Volume 12:Number 6(2016) Page Start: 681 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
25. Trop-2 Overexpression in Poorly Differentiated Endometrial Endometrioid Carcinoma: Implications for Immunotherapy With hRS7, a Humanized Anti–Trop-2 Monoclonal Antibody. Issue 9 (1st November 2011) Authors: Bignotti, Eliana; Ravaggi, Antonella; Romani, Chiara; Falchetti, Marcella; Lonardi, Silvia; Facchetti, Fabio; Pecorelli, Sergio; Varughese, Joyce; Cocco, Emiliano; Bellone, Stefania; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D. Journal: International journal of gynecological cancer Issue: Volume 21:Issue 9(2011) Page Start: 1613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
26. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Issue 14 (12th April 2013) Authors: Roque, Dana M.; Bellone, Stefania; English, Diana P.; Buza, Natalia; Cocco, Emiliano; Gasparrini, Sara; Bortolomai, Ileana; Ratner, Elena; Silasi, Dan‐Arin; Azodi, Masoud; Rutherford, Thomas J.; Schwartz, Peter E.; Santin, Alessandro D. Journal: Cancer Issue: Volume 119:Issue 14(2013) Page Start: 2582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
27. Tubulin‐β‐III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones. Issue 14 (12th April 2013) Authors: Roque, Dana M.; Bellone, Stefania; English, Diana P.; Buza, Natalia; Cocco, Emiliano; Gasparrini, Sara; Bortolomai, Ileana; Ratner, Elena; Silasi, Dan‐Arin; Azodi, Masoud; Rutherford, Thomas J.; Schwartz, Peter E.; Santin, Alessandro D. Journal: Cancer Issue: Volume 119:Issue 14(2013) Page Start: 2582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
28. T‐DM1, a novel antibody–drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo. (2nd June 2014) Authors: English, Diana P.; Bellone, Stefania; Schwab, Carlton L.; Bortolomai, Ileana; Bonazzoli, Elena; Cocco, Emiliano; Buza, Natalia; Hui, Pei; Lopez, Salvatore; Ratner, Elena; Silasi, Dan‐Arin; Azodi, Masoud; Schwartz, Peter E.; Rutherford, Thomas J.; Santin, Alessandro D. Journal: Cancer medicine Issue: Volume 3:Number 5(2014:Oct.) Page Start: 1256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
29. Uterine cancer, mutational phenotype, and the era of immune checkpoint blockade. (4th March 2017) Authors: Roque, Dana M.; Santin, Alessandro D. Journal: Expert review of clinical immunology Issue: Volume 13:Number 3(2017) Page Start: 175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
30. What role does adjuvant therapy play in the management of endometrial cancer?. (2nd January 2023) Authors: Huang, Gloria Shining; Tymon-Rosario, Joan; Santin, Alessandro D. Journal: Expert opinion on pharmacotherapy Issue: Volume 24:Number 1(2023) Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗